https://www.selleckchem.com/pr....oducts/L-Adrenaline-
ith driver mutation-negative advanced NSCLC and poor PS complicated with COPD, with no significant difference between the two regimens. Chinese Clinical Trial Registry ChiCTR-IPR-15006164. Chinese Clinical Trial Registry ChiCTR-IPR-15006164. To investigate the differences in treatment effect sizes between progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with programmed cell death 1 (PD-1) and its ligand (PD-L1) blockade-based treatments. The differences in
Like
Comment
Share
